title: Deferasirox in thalassemia patients with end-stage renal disease.
authors.affiliation: Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon.
authors.forename: Hassan G
authors.initials: HG
authors.lastname: Beydoun
authors.affiliation: Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana.
authors.forename: Antoine N
authors.initials: AN
authors.lastname: Saliba
authors.affiliation: Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon. ataher@aub.edu.lb.
authors.forename: Ali T
authors.initials: AT
authors.lastname: Taher
mesh_terms: D001565:Benzoates / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D000077588:Deferasirox; D005260:Female; D006801:Humans; D007502:Iron Chelating Agents / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D007676:Kidney Failure, Chronic / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D013789:Thalassemia / Q000188:drug therapy*; D014230:Triazoles / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*
chemical_list: D001565:Benzoates; D007502:Iron Chelating Agents; D014230:Triazoles; D000077588:Deferasirox